Superior Outcomes With Bortezomib Or Thalidomide Incorporated Into Autologous Stem Cell Transplantation (ASCT) Versus Novel Agent-Based Treatments For Elderly Patients With Newly Diagnosed Multiple Myeloma (MM): A Case-Match Comparison